LOTTE BIOLOGICS Expands Global CDMO Capabilities with ADC Facility and Strategic Partnerships

LOTTE BIOLOGICS, a rising player in the global Contract Development and Manufacturing Organization (CDMO) market, has announced significant expansions to its capabilities and infrastructure. The company is positioning itself as a major competitor in the biologics manufacturing space, with a focus on antibody-drug conjugates (ADCs) and large-scale production facilities.

ADC Facility Expansion in Syracuse

LOTTE BIOLOGICS has completed a substantial expansion of its ADC manufacturing capabilities at its Syracuse Bio Campus in New York. The company invested approximately $100 million to establish advanced ADC production infrastructure, including conjugation suites with capacities of up to 1,000L. This expansion solidifies the site's position as a North American production hub for next-generation biologics.

The new ADC facility boasts state-of-the-art features, including:

• Advanced safety design
• Cross-contamination prevention systems
• High-efficiency production lines
• Rigorous quality controls

These enhancements enable LOTTE BIOLOGICS to respond agilely to the growing demand for next-generation biologics. The company has also developed a proprietary ADC platform called SoluFlex Link™, which improves linker-payload solubility and ADC hydrophilicity, ultimately enhancing drug stability and efficacy.

Strategic Partnerships and Global Expansion

LOTTE BIOLOGICS is actively pursuing strategic collaborations with leading domestic and global biotech companies across various domains. In April, the company signed its first ADC production agreement with an Asia-based biotech company for a clinical candidate, marking the official launch of its efforts to expand ADC CDMO partnerships.

The company's global strategy includes:

1. Leveraging the Syracuse Bio Campus as a One-Stop CDMO Hub for antibodies and ADCs in North America
2. Developing a large-scale commercial bio campus in Songdo, Korea, with the first plant scheduled to begin operations in 2027
3. Participating in major global events such as BIO International Convention, JP Morgan Healthcare Conference, CPhI Worldwide, and World ADC Summit to increase brand awareness and engage with potential clients

LOTTE BIOLOGICS has already secured contract manufacturing deals with global pharmaceutical companies based in the U.S., publicly listed biotechs, and European firms. The company attributes its success in part to the quality competitiveness and global production track record of the Syracuse facility, which it acquired from Bristol Myers Squibb in 2022.

Future Outlook and Ongoing Developments

As LOTTE BIOLOGICS continues to expand its capabilities and client base, the company is seeing increased interest from potential partners. A company representative stated, "As the operational timeline for the Songdo Bio Campus becomes clearer, discussions with multiple companies for new contracts are also becoming more concrete. We're seeing increased site visits from potential clients at both the Syracuse and Songdo sites."

The company's dual manufacturing strategy, with bases in North America and Asia, is designed to create synergies and offer clients flexible, high-quality manufacturing options. As LOTTE BIOLOGICS moves forward with its expansion plans, it aims to establish itself as a leading player in the global CDMO market, particularly in the rapidly growing field of ADC development and manufacturing.